PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 CheckMate -8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to investigator’s choice of chemotherapy (mFOLFOX-6 or FOLFIRI with or without bevacizumab or cetuximab) as a first-line treatment for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). The dual immunotherapy combination of Opdivo and Yervoy d ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU) to be held from January 25-27 in San Francisco, California, highlighting the company’s progress in making long-term survival outcomes a possibility for more patients with genitourinary cancers, as well as showcasing potential new options and therapeutic platforms that may transform treatment paradigms across tu ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $50, moving -0.62% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.37%. Elsewhere, the Dow saw a downswing of 0.62%, while the tech-heavy Nasdaq depreciated by 0.19%.The biopharmaceutical company's shares have seen a decrease of 2.01% over the last month, not keeping up with the Medical sector's gain of 4.61% and the S&P 500's gain of 1.56%.The investment community will be paying close attent ...

BlackJack3D Yet another cheap Big Pharma stock Having recently written about the cratered pharma stock and value opportunity in Pfizer (PFE), charting the big pharma sell-offs, reveals a nearly as strong downtrend in Bristol-Myers Squibb (NYSE:BMY). The company is in a similar phase of R&D cycling and acquisitions to fill its next cycle of drugs for the next decade. Bristol Myers does not have the stigma around it from being a vaccine producer during COVID-19, but they also have their issues to reckon w ...

DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: PEAK) (“Healthpeak”), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced that it has formed a new strategic joint venture with Breakthrough Properties (“Breakthrough”) through a sale of a 65% interest in Healthpeak’s fully leased Callan Ridge lab campus in the Torrey Pines submarket of San Diego. The formation of the 65% Breakthrough / 35% Healthpeak joint venture values Callan Ridge at ...

股市趋势 - 2022年末，投资者对股市持怀疑态度，但长期来看，美国股市有持续上涨的记录[1] - 第四年的新总统任期通常会看到股市在夏末至年底之间强劲上涨[2] 行业展望 - 2024年，半导体和人工智能相关股票以及生物科技和医疗保健股票有望表现突出[4][7][9][11]

公司投资策略 - 公司认为市场将出现广泛的涨势，由2023年表现不佳的几个行业引领[1] - 公司开始加大在辉瑞（PFE）的持仓，并寻找其他被低估的公司[1] 布里斯托-迈尔斯斯奎布公司（BMY）股价分析 - BMY股价已经触底，公司认为其估值吸引人，计划增加持仓[2] - BMY在财务方面表现良好，具有高利润率和现金流，没有明显的风险[3] BMY未来发展策略 - BMY缺乏增长，但是具有高盈利能力，正在通过收购来刷新未来产品线[6]

股价表现 - Bristol Myers Squibb (BMY) 最新收盘价为 $51.28，较前一天下跌了 -0.98%。这一变化落后于标普500指数当天的下跌幅度为 0.15% [1] - 过去一个月，这家生物制药公司的股价上涨了 1.37%，但落后于医疗行业的 6.58% 和标普500指数的 3.5% [2] 财报预测 - Bristol Myers Squibb 即将发布的财报备受投资者关注，预计于 2024年2月2日发布。预计每股收益为 $1.73，较去年同期下降了 4.95%。同时，Zacks Consensus Estimate 预测公司的净销售额为 111.4 亿美元，较去年同期下降了 2.31% [3] 分析师预测 - 分析师对 Bristol Myers Squibb 的最新预测变化值得关注，这些变化反映了近期业务趋势的不断变化。因此，预测的积极变化表明分析师对公司的业务和盈利能力持乐观态度 [4] Zacks Rank 评级 - Zacks Rank 系统的评级范围在 1（强热门）到 5（强卖出）之间，经外部审计证实，自 1988年以来，排名为 1 的股票的平均年回报率为 +25%。Zacks Consensus EPS 预测在过去一个月内下调了 0.63%。Bristol Myers Squibb 目前是 Zacks Rank 4（卖出） [6] 估值和行业比较 - 就估值而言，Bristol Myers Squibb 目前的前瞻市盈率为 7.06。相对于行业平均的前瞻市盈率 23.03，这表示折价交易 [7] - 与此同时，BMY 的 PEG 比率目前为 1.41。PEG 比率类似于常用的市盈率，但该参数还包括公司预期的盈利增长轨迹。昨日收盘价下，医疗 - 生物医学和遗传学行业的平均 PEG 比率为 1.93 [8] 行业排名 - 医疗 - 生物医学和遗传学行业属于医疗行业。目前，该行业的 Zacks Industry Rank 为 66，位居 250 多个行业的前 27% [9] - Zacks Industry Rank 通过测量各个行业组内个别股票的平均 Zacks Rank 来衡量我们各个行业组的实力。我们的研究显示，排名前 50% 的行业胜过后 50% 的行业的比例为 2比1 [10]

Bristol-Myers Squibb CEO Chris Boerner detailed the pharmaceutical giant's bundle of recent acquisitions in a Monday interview with CNBC's Jim Cramer, and indicated the company is in a transformative stage."We are writing the next chapter of this company," Boerner said. "And we've got real financial strength that has enabled us to go and actually bring innovation in to the company from outside. And that's what we've done with these most recent deals."Bristol-Myers Squibb announced three multi-billion-dollar ...

公司展望 - 公司有望成为本行业增长最快的公司之一[6] - 公司计划通过加强研发和资本配置来实现可持续增长[10] - 公司拥有丰富的产品管线，计划在未来十年内推出超过16种新产品，大部分为首创或最佳产品[28] 产品和技术发展 - 公司在肿瘤学领域拥有多个产品线，包括Opdivo和Breyanzi，计划在未来扩大患者群体[13] - 公司在心血管疾病领域致力于扩大在心肌病和心力衰竭治疗方面的领先地位，并继续发展在血栓形成领域的产品[19] - 公司在免疫学和神经科学领域有布局，包括推出新药物Sotyktu和LPA1，以及收购Karuna公司加速进入神经科学领域[22] 资本配置和战略 - 公司将继续战略性地配置资本，包括外部创新、保持强劲资产负债表和回报股东[31] - 公司将继续关注许可机会、合作伙伴关系和并购，以增强现有治疗领域的深度[32] - 公司将继续在资本分配方面保持战略性，包括通过业务发展和股东回报来源创新[43]